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MEETING PROCEEDINGSThe 20th Annual Transcatheter Cardiovascular Therapeutics
(TCT) Meeting, TCT 2008, was held in Washington, DC,
October 12 through 17, 2008. TCT is the largest meeting in
the world devoted to transcatheter therapies and is predomi-
nantly an interventional cardiology meeting. For the second
year, a program was offered for cardiac surgeons to help
bring the specialty into this rapidly progressing and exciting
field. Although there were many significant trials, mostly
pertaining to the treatment of coronary artery disease (as
described here), the meeting focused extensively on demon-
strating procedures and highlighting new technologies.
TRANSCATHETER VALVE THERAPY
One of the better-attended sessions was the valvular heart
disease summit. This included an excellent review of current
surgical procedures but focused mainly on emerging trans-
catheter techniques. The summit provided updated experi-
ences with current devices, as well as first human trials
and preliminary work for many devices on the horizon. Al-
though the data are largely encouraging, most work is pre-
liminary and not really appropriate for discussion until
more data become available. Two systems are currently ap-
proved for use in Europe and have been applied with vari-
able but generally encouraging success.
CoreValve
The experience from Siegburg, Germany, with the 18F
self-expanding CoreValve system (CoreValve Inc, Irvine,
Calif) was presented.1 Implant success was 97.1%, with no
procedural mortality. The 30-day mortality was 10.8%,
with a stroke rate of 2.9%. The 1-year survival was
84.3%. No patient had residual aortic stenosis, and all had
improvement in symptoms. Relative to baseline, 34.6% of
patients had a reduction of aortic insufficiency, 34.6% had
no change, and 30.9% hadworsening of aortic insufficiency.
SAPIEN Valve
An experience with the SAPIEN transcatheter aortic valve
(Edwards Lifesciences LLC, Irvine, Calif) was presented
from Vancouver, BC, Canada, the site with the largest
worldwide experience.2 The data were generally impressive.
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cases into tertiles. The first tertile had an implant success
of 81.6%, which improved in both the second and third ter-
tiles to 97.4%. The 30-day mortality in this same group went
from 13.2% in the first tertile to 10.5% in the second and
0% in the third.
TRAVERSE
TRAVERSE3 is the European feasibility study of the
transapical approach with the Edwards transcatheter aortic
valve. There were 168 patients in a 3.5-year period. The im-
plant success was 92.8%. Cardiopulmonary bypass was
used in 23% of cases, and 7.1% of patients required conver-
sion to a sternotomy. The 30-day survival was 85%, and the
6-month survival was 70%. This experience compared fa-
vorably with the US REVIVAL II transapical experience
(6-month survival 64%) and particularly the PARTNER
EU Transapical experience (6-month survival 56%).
AMADEUS
AMADEUS4 (cArillon Mitral Annuloplasty Device
European Union Study) is a feasibility trial evaluating the
CARILLON device (Cardiac Dimensions Inc, Kirkland,
Wash).4 CARILLON is a mitral annuloplasty device im-
planted percutaneously into the coronary sinus. The device
can be retrieved during the procedure if there is no acute suc-
cess. Among the 43 patients in whom placement was at-
tempted, 30 received permanent devices because of acute
reduction in mitral regurgitation (mitral regurgitation from
grade 3 to 2, P< .001). The coronary artery was crossed
in 84% of patients but only caused compromise necessitat-
ing device removal in 6 patients. In the last 10 patients, the
procedure time averaged 10 minutes.
MANAGEMENT OF CORONARYARTERY
DISEASE
Most of the major trials presented at TCT pertained to per-
cutaneous coronary intervention (PCI) for coronary artery
disease. Some of the more relevant are described here.
SYNTAX
The SYNTAX trial5,6 (SYNergy between PCI with
TAXUS and Cardiac Surgery) was a randomized trial com-
paring PCI with TAXUS drug-eluting stents (Boston Scien-
tific Corporation, Natick, Mass) against coronary artery
bypass grafting (CABG) in patients with complex coronary
artery disease. The results had previously been presented at
the European Society of Cardiology. At the TCT meeting,
two more in-depth subanalyses were provided to furtherardiovascular Surgery c Volume 137, Number 2 509
Meeting Proceedings Williamsdelineate the left main (CABG n¼ 345, PCI n¼ 528) and tri-
ple-vessel (CABG n¼ 549, PCI n¼ 546) groups. It is impor-
tant to note that these data only provide outcomes at 1 year.
In the patients with unprotected left main disease the inci-
dences of major adverse cardiac and cerebrovascular events
(MACCEs) at 1 year was similar for CABG and PCI (13.6%
vs 15.8%, P¼ .44). Patients undergoing CABG had a lower
rate of repeat revascularization (6.7% vs 12.0%, P ¼ .02),
but at the expense of a significantly higher stroke rate
(2.7%, vs 0.3%, P ¼ .009). If these patients were broken
down by the complexity of their lesions (SYNTAX score),
there was no difference in MACCE rate between CABG
and PCI in the cases of low and intermediate complexity.
In the high-complexity cases, the MACCE rate was signifi-
cantly higher in the PCI group (12.9% vs 25.3%, P¼ .008).
In patients with triple-vessel disease, the MACCE, myo-
cardial infarction (MI), and repeat revascularization rates
were all higher in the PCI group (Table 1). The exception
to this was the group with a low SYNTAX score, in which
MACCE rates were similar for PCI and CABG.
FAME
The FAME trial7 (Fractional Flow Reserve versus Angi-
ography for Guiding PCI in Patients with Multivessel Coro-
nary Artery Disease) randomly assigned patients with
multivessel disease to undergo either angiographically
guided PCI or fractional flow reserve (FFR)–guided PCI.
FFR is a hemodynamic rather than visual assessment of a le-
sion. It essentially compares the pressure on either side of
a lesion during maximal hyperemia (achieved with adeno-
sine) by advancing a special wire with a small pressure trans-
ducer across a lesion. Any lesion with a postlesion/prelesion
ratio lower than 0.80 is considered significant. A total of
1000 patients were randomly assigned (angiographically
guided n ¼ 496, FFR guided n ¼ 509). Patients in the
FFR group had a reduced number of stents used, less con-
trast agent used, and lower overall cost. More importantly,
they also had lower rates of major adverse cardiac events
(MACEs, 13.2% vs 18.%, P ¼ .02) and of death or MI
(7.3% vs 11.1%, P ¼ .04).
HORIZONS AMI
HORIZONS AMI8 (Harmonizing outcomes with Revas-
cularization and Stents in Acute Myocardial Infarction)
was a study with two primary purposes. The first was to
demonstrate the optimal anticoagulation regimen for pa-
tients having PCI for AMI. The second was to compare
the use of bare metal against that of drug-eluting stents in
the same population. The anticoagulation arm had been pub-
lished and presented previously (TCT 2007) and demon-
strated the use of bivalirudin alone as superior to the use
of heparin with a glycoprotein IIb/IIIa inhibitor.9 A total
of 3000 patients had been enrolled in the stent arm of the
trial, which used either a TAXUS drug-eluting stent or an510 The Journal of Thoracic and Cardiovascular SurExpress bare metal stent (same platform but without drug
and polymer, also from Boston Scientific), randomly allo-
cated in a 3:1 fashion. There was no difference in overall
MACE rate, which included stent thrombosis at 1 year, be-
tween drug-eluting and bare metal stent groups (8.1% vs
8.0%, P ¼ .92). Drug-eluting stents were associated with
a significantly lower incidence of revascularization in the
target lesion (4.5% vs 7.5%, P ¼ .002).
BBC ONE
BBC ONE10 (British Bifurcation Coronary Study: Old,
New, and Evolving Stategies) was a randomized trial to
evaluate ideal stent management for bifurcation lesions. A
total of 500 patients were randomly allocated to two arms.
Patients in the first group were treated with a simple strategy
in which the main vessel lesion was stented and the side
branch underwent angioplasty and provisional stenting.
Those in the second group were treated with a complex strat-
egy involving coverage of the entire lesion with stents in
both branches through more complex techniques. The pa-
tients with the simple strategy had a lower periprocedural
MACE rate (2.0% vs 7.6%, P ¼ .003) and also benefited
from shorter procedures with less resource use. At 9 months
of follow-up, the composite end point of death, MI, or target
vessel failure was significantly lower with the simple strat-
egy (8.0% vs 15.2%, P ¼ .009). The individual end points
were also lower in the simple strategy, but only the MI end
point achieved significance.
MAIN-COMPARE
MAIN-COMPARE11 (Revascularization for Unprotected
Left Main Coronary Artery Stenosis: Comparison of Percu-
taneous Coronary Angioplasty vs Surgical Revasculariza-
tion) is a registry study from Korea that compares CABG
against PCI for left main coronary artery disease. An update
including 3-year follow-up was provided from the registry.
With propensity matching, there were no differences in sur-
vival, Q-wave MI, or stroke between CABG and PCI
groups. Patients undergoing CABG, however, had a signifi-
cantly lower rate of revascularization at 3 years (2.6% vs
9.3%, P< .001).
COOL-RCN
COOL-RCN12 (Cooling to Prevent Radio Contrast Ne-
phropathy inPatientsUndergoingDiagnostic or Interventional
Catheterization) was a trial that used systemic hypothermia
TABLE 1. Triple-vessel disease: Outcomes at 1 year
End point CABG (n ¼ 549) PCI (n ¼ 546) P value
MACCE 11.2% 19.1% <.001
Myocardial infarction 2.6% 5.2% .04
Repeat revascularization 5.4% 14.7% <.001
CABG, Coronary artery bypass grafting; PCI, percutaneous coronary intervention;
MACCE, major adverse cardiac and cerebrovascular event.gery c February 2009
Williams Meeting Proceedings(33–34C) in hopes of preventing radiocontrast-induced ne-
phropathy in patients at high risk for this complication. The
trial therapy was randomly allocated against a normothermia
arm. The primary end point was radiocontrast-induced ne-
phropathy at 96 hours. There were 70 patients in the normo-
thermia arm and 58 patients in the hypothermia arm. The
serum creatinine levels did not differ at baseline. There was
no beneficial effect of hypothermia on serum creatinine at ei-
ther 24 hours (1.55 mg/dL vs 1.91 mg/dL, P ¼ .30) or 48
hours (1.94 mg/dL vs 2.21 mg/dL, P ¼ .09). Contrast-in-
duced nephropathy occurred in 18.6% of the control group
and 22.4% of the hypothermia group (P ¼ .59). The study
was limited by the inability to enroll the expected 400 pa-
tients and the fact that the study was based on an expected
rate of nephropathy in the control group of 35%.
DECREASE
DECREASE13 is a registry study from South Korea that
compares double antiplatelet therapy (aspirin and clopidog-
rel) against triple antiplatelet therapy (aspirin, clopidogrel
and cilostazol) in patients receiving drug-eluting stents.
The study was conducted on a single-center registry of
1443 patients receiving triple antiplatelet and 1656 patients
receiving double antiplatelet therapy. Triple antiplatelet
therapy was found to reduce significantly the 12-month
risk of stent thrombosis (hazard ratio 0.108, 95% confidence
interval 0.013–0.918, P¼ .415). Additionally, in an analysis
of propensity-matched pairs, the thrombosis incidence in the
triple therapy group was lower (0.1% vs 0.8%, P ¼ .0192).
There was no difference in bleeding rate between the groups.
PREPARE
The PREPARE trial14 (Prospective Randomized Trial of
Proximal Microcirculatory Protection in Patients with Acute
Myocardial Infarction Undergoing Primary PCI) was a ran-
domized trial in patients with ST-segment elevation MI that
compared traditional therapy against proximal embolic pro-
tection with the Proxis device (St Jude Medical Inc, Minne-
apolis, Minn). The Proxis device is essentially a large-lumen
catheter with a low-pressure balloon at the end. The catheter
is placed in the infarct-related coronary artery, and the bal-
loon is then inflated, which occludes proximal flow. In the-
ory, this allows the lesion to be crossed and any thrombotic
material to be aspirated, rather than breaking up the throm-
bus and allowing downstream embolization. There were
141 patients in the device arm and 143 in the control arm.
The patients who received proximal embolic protection
had immediate ST-segment resolution 66% of the time, ver-
sus 50% in the control group (P ¼ .009).
CONCLUSION
The TCT 2008 meeting had many significant studies,
most of which are especially relevant to the practicing inter-The Journal of Thoracic and Cventional cardiologist. There were, however, many compo-
nents directly or indirectly relevant to the cardiac surgeon.
In the realm of coronary artery disease, the data are still rel-
atively short term. In general, the role of cardiac surgery in
complex multivessel disease is perhaps more solidified. In-
creasing amounts of data, however, suggest that PCI will
play an increasing role in the treatment of left main coronary
artery disease. The treatment of valvular heart disease with
transcatheter techniques is evolving rapidly. Although prob-
ably many devices will fail, no doubt some will be success-
ful. These devices will have a direct impact on our specialty
and on the way that patients with valvular heart disease are
treated. It is to be hoped that programs such as that offered at
TCT will allow those in our specialty to become leaders
with these new technologies, rather than victims of their
success.
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